Showing results (141-150 of 218) with videos related to
Sort By:
Pageof 22
BMC Systems Biology|July 6, 2013
The systems biology simulation core algorithmRoland Keller, Alexander Dörr, Akito Tabira, et al.The Lancet. Gastroenterology & Hepatology|December 4, 2018
A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensusRebecca Fish, Caroline Sanders, Richard Adams, et al.BMC Systems Biology|December 17, 2011
Reproducible computational biology experiments with SED-ML--the Simulation Experiment Description Markup LanguageDagmar Waltemath, Richard Adams, Frank T Bergmann, et al.Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
Selection-guided discovery in South Asians implicates the MAPT locus in insulin resistanceErwan Pennarun, Borbala Banfalvi, Yuemin Li, et al.Journal of Clinical Pathology|September 10, 2015
Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trialSusan D Richman, Richard Adams, Phil Quirke, et al.International Journal of Radiation Oncology, Biology, Physics|October 21, 2019
Patterns and Predictors of Relapse Following Radical Chemoradiation Therapy Delivered Using Intensity Modulated Radiation Therapy With a Simultaneous Integrated Boost in Anal Squamous Cell CarcinomaRebecca Shakir, Richard Adams, Rachel Cooper, et al.Plos One|September 26, 2018
Systematic review update of observational studies further supports aspirin role in cancer treatment: Time to share evidence and decision-making with patients?Peter C Elwood, Janet E Pickering, Gareth Morgan, et al.Clinical Colorectal Cancer|June 13, 2026
Prognostic Value of Liver Metastases and KRAS Mutations in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Third-Line Placebo-Controlled Trials From the ARCAD CRC DatabaseThomas Samaille, Morteza Raeisi, Romain Cohen, et al.British Journal of Cancer|August 18, 2018
A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUSSimon Gollins, Nicholas West, David Sebag-Montefiore, et al.The Lancet. Oncology|April 8, 2014
Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trialHarpreet Wasan, Angela M Meade, Richard Adams, et al.Pageof 22